# CLINICAL TRIAL FACT SHEET

Clinicaltrials.gov Identifier: NCT03275285

## A phase III, randomized, open-label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines of therapy

## (IKEMA study)

### Trial Description:

Approximately 300 patients who have already been treated for myeloma with from one to three prior therapy regimens will be randomly assigned by a computer to one of two groups called study "arms." Patients will know to which arm they have been assigned. Patients in the experimental arm will receive the combination of anti-CD38 monoclonal antibody isatuximab (formerly known as SAR650984) plus carfilzomib (brand name Kyprolis®) and dexamethasone (IKd), and patients in the other arm will receive carfilzomib plus dexamethasone (Kd).

### Trial Objectives:

The primary objective of this trial is to determine the possible benefit of isatuximab in combination with carfilzomib and dexamethasone in prolonging the length of response time (progression-free survival, or PFS) as compared to carfilzomib and dexamethasone. Other objectives include evaluating the following:

- Overall response rate (ORR).
- Rate of complete response (CR) with minimal residual disease (MRD) negativity in both study arms.
- Safety of therapy in both study arms.
- Duration of response in both study arms.
- How isatuximab in combination with carfilzomib is metabolized by the body.
- Quality of life, disease and treatment-related symptoms, impact on the healthcare system, and health status of all trial participants.

### Trial Design:

**Experimental Arm**

- Patients will receive 4-week cycles of isatuximab intravenously (IV, or into a vein) on days 1, 8, 15, and 22 of the 1st cycle, then on day 1 and 15 of subsequent cycles along with carfilzomib.
- Patients will receive carfilzomib intravenously on days 1, 2, 8, 9, 15, and 16 of each 4-week cycle.
- Patients will receive dexamethasone intravenously or by mouth twice a week during each 4-week cycle.

**Comparator Arm**

- Patients will receive intravenous carfilzomib on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
- Patients will receive intravenous or oral dexamethasone twice weekly.
- Patients will receive oral or IV dexamethasone on days 1, 8, 15, and 22 of each 4-week cycle.

*(continues on next side)*

International Myeloma Foundation®

**International Myeloma Foundation**
12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA
Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 (worldwide) • TheIMF@myeloma.org • myeloma.org

# CLINICAL TRIAL FACT SHEET

Clinicaltrials.gov Identifier: NCT03275285

## A phase III, randomized, open-label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines of therapy

## (IKEMA study)

*(continued)*

### Duration of Treatment:

- The screening period for this study is up to 3 weeks long.
- Patients will continue study treatment until disease progression, unacceptable adverse reaction (side effect), patient's wish, or other reason for discontinuation.
- Patients who discontinue the study treatment due to disease progression will be followed every 3 months for further anti-myeloma therapies, progression-free survival (remission) after further therapy, and for survival.
- Patients who discontinue the study treatment before disease progression is documented will be followed-up every 4 weeks until confirmation of disease progression, then every 3 months for further anti-myeloma therapies, progression-free survival (remission duration) after further therapy, and survival.
- After progression-free survival (remission duration) analysis, patients will be followed yearly for 3 years.

### Inclusion Criteria:

- Myeloma previously treated with 1–3 lines of therapy.
- Measurable M-protein (≥ 0.5 g/dL) and/or urine M-protein (≥ 200 mg/24 hours).

### Exclusion Criteria:

- Previous treatment with carfilzomib and failure to achieve at least one minor response (≥ 25% drop in monoclonal protein level) during previous therapies and/or last previous therapy completed within last 14 days.
- Disease measurable only by free light chain level.
- Poor overall health status.
- Patients with a history of the following heart conditions: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association class III or IV congestive heart failure, ≥ grade 3 arrhythmias, stroke or transient ischemic attack within the last 6 months, and/or left ventricular ejection fraction lower than 40%.
- Previous cancer unless disease-free for > 5 years, or cancer that didn't spread to other tissue and was curatively treated.
- Known acquired immunodeficiency syndrome-related illness or illness requiring antiretroviral treatment, or hepatitis A, B, or C active infection.
- Females of childbearing potential, or male patients with female partners who are of childbearing potential, who do not agree to use a highly effective method of birth control.

*(continues on next page)*

**International Myeloma Foundation**
12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA
Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 (worldwide) • TheIMF@myeloma.org • myeloma.org

# CLINICAL TRIAL FACT SHEET

Clinicaltrials.gov Identifier: NCT03275285

## A phase III, randomized, open-label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines of therapy

## (IKEMA study)

*(continued)*

### Locations Enrolling Patients and Contact Information:

For site information, send an email including one or more of the below site numbers to **Contact-Us@sanofi.com**

**Australia**
Investigational Site Number 0360008
Nedlands, Australia, 6009

Investigational Site Number 0360002
Wollongong, Australia, 2500

**Czechia**
Investigational Site Number 2030002
Brno, Czechia, 62500

Investigational Site Number 2030003
Ostrava - Poruba, Czechia, 70852

Investigational Site Number 2030001
Praha 2, Czechia, 12808

**France**
Investigational Site Number 2500001
Nantes Cedex 01, France, 44093

Investigational Site Number 2500006
Paris Cedex 12, France, 75571

**Japan**
Investigational Site Number 3920005
Morioka-Shi, Japan

Investigational Site Number 3920004
Shibuya-Ku, Japan

Investigational Site Number 3920003
Sunto-Gun, Japan

Investigational Site Number 3920001
Suwa-Shi, Japan

Investigational Site Number 3920002
Yamagata-Shi, Japan

**Korea, Republic of**
Investigational Site Number 4100001
Seoul, Korea, 03080

Investigational Site Number 4100002
Seoul, Korea, 06351

**New Zealand**
Investigational Site Number 5540002
Wellington, New Zealand

**Turkey**
Investigational Site Number 7920001
Ankara, Turkey, 06500

Investigational Site Number 7920002
İstanbul, Turkey



**International Myeloma Foundation**
12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA
Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 (worldwide) • TheIMF@myeloma.org • myeloma.org